TITLE

Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant

AUTHOR(S)
Machuca, Eduardo; Hummel, Aurélie; Nevo, Fabien; Dantal, Jacques; Martinez, Frank; Al-Sabban, Essam; Baudouin, Véronique; Abel, Laurent; Grünfeld, Jean-Pierre; Antignac, Corinne
PUB. DATE
April 2009
SOURCE
Kidney International;Apr2009, Vol. 75 Issue 7, p727
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Mutations of NPHS2, encoding podocin, are the main cause of autosomal recessive steroid-resistant nephrotic syndrome (NS) presenting in childhood. Adult-onset steroid-resistant NS has been described in patients heterozygous for a pathogenic NPHS2 mutation together with the p.R229Q variant. To determine the frequency and the phenotype of patients carrying the p.R229Q variant, we sequenced the complete coding region of NPHS2 in 455 families (546 patients) non-responsive to immunosuppressive therapy or without relapse after transplantation. Among affected Europeans, the p.R229Q allele was significantly more frequent compared to control individuals. Thirty-six patients from 27 families (11 families from Europe and 14 from South America) were compound heterozygotes for the p.R229Q variant and one pathogenic mutation. These patients had significantly later onset of NS and end stage renal disease than patients with two pathogenic mutations. Among 119 patients diagnosed with NS presenting after 18 years of age, 18 patients were found to have one pathogenic mutation and p.R229Q, but none had two pathogenic mutations. Our study shows that compound heterozygosity for p.R229Q is associated with adult-onset steroid-resistant NS, mostly among patients of European and South American origin. Screening for the p.R229Q variant is recommended in these patients along with further NPHS2 mutation analysis in those carrying the variant.Kidney International (2009) 75, 727–735; doi:10.1038/ki.2008.650; published online 14 January 2009
ACCESSION #
36893243

 

Related Articles

  • Variability in phenotype induced by the podocin variant R229Q plus a single pathogenic mutation. Phelan, Paul J.; Hall, Gentzon; Wigfall, Delbert; Foreman, John; Nagaraj, Shashi; Malone, Andrew F.; Winn, Michelle P.; Howell, David N.; Gbadegesin, Rasheed // Clinical Kidney Journal;Oct2015, Vol. 8 Issue 5, p538 

    Background: Mutations in podocin (NPHS2) are the most common cause of childhood onset autosomal recessive steroid-resistant nephrotic syndrome (SRNS). The disease is characterized by early-onset proteinuria, resistance to immunosuppressive therapy and rapid progression to end-stage renal...

  • Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Kranz, Birgitta; Vester, Udo; Büscher, Rainer; Wingen, Anne-Margret; Hoyer, Peter F. // Pediatric Nephrology;Apr2008, Vol. 23 Issue 4, p581 

    The impact of cyclosporine A (CsA) therapy in patients with steroid-dependent nephrotic-syndrome (SDNS) on long-term renal function is controversial. Data beyond 5 years are rare. Long-term renal function was evaluated in children with SDNS with and without CsA therapy, especially beyond 5...

  • Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Benz, Kerstin; Dötsch, Jörg; Rascher, Wolfgang; Stachel, Daniel // Pediatric Nephrology;Jul2004, Vol. 19 Issue 7, p794 

    A 16-year-old patient with steroid-dependent nephrotic syndrome with more than 35 relapses developed severe relapsing idiopathic thrombocytopenic purpura (ITP). At the age of 2 years, nephrotic syndrome was diagnosed and successfully treated with a standard prednisone regimen. Frequent relapses...

  • A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Ponticelli, Claudio; Rizzoni, Gianfranco; Edefonti, Alberto; Altieri, Paolo; Rivolta, Emilio; Rinaldi, Stefano; Ghio, Luciana; Lusvarghi, Egidio; Gusmano, Rosanna; Locatelli, Francesco; Pasquali, Sonia; Castellani, Alfonso; Della Casa-Alberighi, Ornella // Kidney International;Jun1993, Vol. 43 Issue 6, p1377 

    To compare the efficacy (induction of remission) and safety of cyclosporine (CsA) with those of supportive therapy in patients with steroid-resistant idiopathic nephritic syndrome (INS), we organized an open, prospective, randomized, multicentric, controlled study for parallel groups, stratified...

  • ROLE OF SIROLIMUS IN STEROID RESISTANT IDIOPATHIC NEPHROTIC SYNDROME (SRNS). Sharma, R. K.; Vinod, P. B.; Saxena, A.; Gupta, A.; Kumar, A.; Prasad, N. // Indian Journal of Nephrology;Jul-Sep2007, Vol. 17 Issue 3, p99 

    This study was conducted to evaluate the safety and efficacy of sirolimus (SRL) in patients with SRNS. This study comprises 19 pts (both children and adults) with SRNS of biopsy proven idiopathic (NS) (6 Minimal change, 13 FSGS). Sirolimus was initiated in a dose of 2 mg once daily increased to...

  • Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome. Shirai, Sayuri; Yasuda, Takashi; Tsuchida, Hiroki; Kuboshima, Shingo; Konno, Yusuke; Shima, Yoshinori; Sato, Takeo; Hatta, Shigeo; Masuhara, Keisou; Kimura, Kenjirou // Clinical & Experimental Nephrology;Apr2009, Vol. 13 Issue 2, p123 

    The present study evaluated the clinical efficacy and pharmacokinetics of microemulsion cyclosporine A (ME-CyA) with modification from postprandial to preprandial administration in adult patients with refractory nephrotic syndrome. We investigated 19 patients with refractory nephrotic syndrome...

  • Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Mendizábal, S.; Zamora, I.; Berbel, O.; Sanahuja, M. J.; Fuentes, J.; Simon, J. // Pediatric Nephrology;Jul2005, Vol. 20 Issue 7, p914 

    Attempts to minimize the effects of prolonged steroid use in steroid-dependent nephrotic syndrome (SDNS) and the need to overcome steroid resistance (SRNS) justifies immunosuppressant therapy. We report our experience in a cohort of patients with SD/SRNS during the administration of...

  • Management of the Nephrotic Syndrome. Linshaw, Michael A.; Gruskin, Alan B. // Clinical Pediatrics;Jan1974, Vol. 13 Issue 1, p45 

    Immunosuppressive agents have been used extensively in the treatment of the nephrotic syndrome, but many problems regarding dosages, appropriate agents, and short- and long-term toxicity require resolution before their use can become generalized. The only group of patients clearly demonstrated...

  • Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Hasselbacher, K.; Wiggins, R. C.; Matejas, V.; Hinkes, B. G.; Mucha, B.; Hoskins, B. E.; Ozaltin, F.; Nürnberg, G.; Becker, C.; Hangan, D.; Pohl, M.; Kuwertz-Bröking, E.; Griebel, M.; Schumacher, V.; Royer-Pokora, B.; Bakkaloglu, A.; Nürnberg, P.; Zenker, M.; Hildebrandt, F. // Kidney International;Sep2006, Vol. 70 Issue 6, p1008 

    Congenital nephrotic syndrome is clinically and genetically heterogeneous. The majority of cases can be attributed to mutations in the genes NPHS1, NPHS2, and WT1. By homozygosity mapping in a consanguineous family with isolated congenital nephrotic syndrome, we identified a potential candidate...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics